Page 43 - AN-3-4

Advanced Neurology Anticoagulants as neuroprotective therapeutics

neuropathogenesis in AD (Figure 2). This therapeutic doi: 10.1038/s41593-018-0238-6
approach could slow the overall progression of cognitive 4. Scheres SH, Ryskeldi-Falcon B, Goedert M. Molecular
and physical decline in AD. Among the currently available pathology of neurodegenerative diseases by cryo-EM of
DOACs, dabigatran, apixaban, and rivaroxaban are amyloids. Nature. 2023;621(7980):701-710.
well positioned for clinical investigation as potential doi: 10.1038/s41586-023-06437-2
neuroprotective drugs in AD. In addition, the FXa inhibitors
edoxaban and betrixaban might also be suitable candidates, 5. Garcia-Morales V, Gonzalez-Acedo A, Melguizo-
Rodriguez L, et al. Current understanding of the
pending the approval of efficient antidote strategies physiopathology, diagnosis and therapeutic approach to
and the availability of more data from observational Alzheimer’s disease. Biomedicines. 2021;9(12):1910.
studies. Whether used alone or in combination with anti-
inflammatory agents, cardiovascular treatments, standard doi: 10.3390/biomedicines9121910
AD therapies, or other disease-modifying agents, DOACs 6. Strickland S. Blood will out: Vascular contributions to
could become part of a novel treatment strategy aimed Alzheimer’s disease. J Clin Invest. 2018;128(2):556-563.
at addressing neurovascular pathology in AD and its doi: 10.1172/JCI97509
associated cognitive decline. 5,15,16,19-27,96
7. Sweeney MD, Montagne A, Sagare, AP, et al. Vascular
Acknowledgments dysfunction-the disregarded partner of Alzheimer’s disease.
Alzheimers Dement. 2019;15(1):158-167.
Cordial thanks go to my wife, Regina, for her great support, doi: 10.1016/j.jalz.2018.07.222
encouragement, and patience.
8. Nucera A, Hachinski V. Cerebrovascular and Alzheimer
Funding disease: Fellow travelers or partners in crime? J Neurochem.
2018;144(5):513-516.
None.
doi: 10.1111/jnc.14283
Conflict of interest 9. Fisher RA, Miners JS, Love S. Pathological changes within
the cerebral vasculature in Alzheimer´s disease: New
The author declares no conflict of interest.
perspectives. Brain Pathol. 2022;32(6):e13061.
Author contributions doi: 10.1111/bpa.13061
This is a single-authored article. 10. Greenberg SM, Bacskai BJ, Hernandez-Guillamon M,
Pruzin J, Sperling R, Van Veluw SJ. Cerebral amyloid
Ethics approval and consent to participate angiopathy and Alzheimer disease-one peptide, two
pathways. Nat Rev Neurol. 2020;16(1):30-42.
Not applicable.
doi: 10.1038/s41582-019-0281-2
Consent for publication 11. Abbott A. Treating Alzheimer’s before it takes hold. Nature.
2022;603(7900):216-219.
Not applicable.
doi: 10.1038/d41586-022-00651-0
Availability of data 12. Sierksma A, Escott-Price V, De Strooper B. Translating
Not applicable. genetic risk of Alzheimer’s disease into mechanistic insight
and drug targets. Science. 2020;370(6512):61-66.
References doi: 10.1126/science.abb8575
1. Stelzmann RA, Schnitzlein HN, Murtagh FR. An english 13. Shabir O, Berwick J, Francis SE. Neurovascular dysfunction
translation of Alzheimer´s 1907 paper, Über eine eigenartige in vascular dementia, Alzheimer’s and atherosclerosis. BMC
Erkrankung der Hirnrinde. Clin Anat. 1995;8(6):429-431. Neurosci. 2018;19:62.
doi: 10.1002/ca.980080612 doi: 10.1186/s12868-018-0465-5
2. Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer´s 14. Jeremic D, Jimenez-Diaz L, Navarro-Lopez JD. Past, present
disease at 25 years. EMBO Mol Med. 2016;8(6):595-608. and future of therapeutic strategies against amyloid-β
doi: 10.15252/emmm.201606210 peptides in Alzheimer’s disease: A systematic review. Ageing
Res Rev. 2021;72:101496.
3. Jucker M, Walker LC. Propagation and spread of pathogenic
protein assemblies in neurodegenerative diseases. Nat doi: 10.1016/j.arr.2021.101496
Neurosci. 2018;21(10):1341-1349. 15. Grossmann K. Direct oral anticoagulants (DOACs) for

Volume 3 Issue 4 (2024) 25 doi: 10.36922/an.3799